Voloridge Investment Management
RCKT icon

Voloridge Investment Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Voloridge Investment Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-274,875
Closed -$673K – 1350
2025
Q2 		$673K Buy
+274,875
New +$1.39M ﹤0.01% 1056
2023
Q4 		– Sell
-11,269
Closed -$231K – 1413
2023
Q3 		$231K Buy
+11,269
New +$205K ﹤0.01% 1310
2022
Q4 		– Sell
-184,455
Closed -$2.94M – 1604
2022
Q3 		$2.94M Sell
184,455
-52,012
-22% -$812K 0.02% 853
2022
Q2 		$3.25M Buy
236,467
+18,360
+8% +$219K 0.02% 840
2022
Q1 		$3.46M Buy
218,107
+163,736
+301% +$2.83M 0.02% 769
2021
Q4 		$1.19M Buy
+54,371
New +$1.48M 0.01% 1230
2021
Q1 		– Sell
-45,448
Closed -$2.49M – 1614
2020
Q4 		$2.49M Buy
+45,448
New +$1.66M 0.02% 659
2020
Q2 		– Sell
-13,811
Closed -$193K – 1458
2020
Q1 		$193K Buy
+13,811
New +$273K 0.01% 964

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Voloridge Investment Management's RCKT Position: Q3 2025 in Review

Voloridge Investment Management sold out of Rocket Pharmaceuticals (RCKT) in Q3 2025, closing a stake of 274,875 shares — an estimated $673K sold.

Voloridge Investment Management first reported a position in RCKT in Q1 2020 and held it in 8 quarters. The position peaked at $3.46M in Q1 2022. 173 funds tracked by Wall St. Rank hold RCKT as of Q3 2025.

  • Voloridge Investment Management reported no remaining Rocket Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Voloridge Investment Management sold 274,875 Rocket Pharmaceuticals shares in Q3 2025, an estimated $673K.
  • Voloridge Investment Management first reported a position in Rocket Pharmaceuticals in Q1 2020 and held it in 8 quarters.
  • Voloridge Investment Management's Rocket Pharmaceuticals position peaked at $3.46M in Q1 2022.
  • 173 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2025.

Based on Voloridge Investment Management's 13F filing for Q3 2025, filed 14 Nov 2025.